WhatsApp Intervention to Assess the Effect of Messages in Adherence to Antiretrovirals in Young People With HIV in Peru

N/AActive Not RecruitingNCT06500013

Universidad Peruana Cayetano Heredia131 enrolled

Overview

The goal of this clinical trial is to learn which type of messages is more efficacious to improve adherence to medication in young people living with HIV. The main question is aims to answer is: -Are messages designed by participants (self-designed) more efficacious than messages designed by health providers to improve adherence to antiretroviral treatment (HIV medications)? Researchers will compare both types of messages to see if one is better than the other in helping participants take their medications. Participants will: * Receive either messages designed by themselves or by health providers for 4 months. * Be able to chat with health providers at any time, with special focus regarding questions about their condition, medications and health services. * Complete questionnaires via WhatsApp describing how they are taking their medications, and how often they forget to take them. * Complete questionnaires via WhatsApp describing their opinion about receiving the messages and being able to chat with health providers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

131

Conditions

HIV

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 29 Years

Medical Language ↔ Plain English

Inclusion Criteria: * People living with HIV of age 18-29 at the moment of signing informed consent. * Being a patient of the study center's Infectious Diseases clinic or National HIV Program, between March 2024 and July 2024. * Ownership of a mobile phone that supports WhatsApp. Exclusion Criteria: * Being pregnant at the moment of signing informed consent. * Being illiterate at the moment of signing informed consent. * Being blind at the moment of signing informed consent

Outcomes

Primary Outcomes

Change from Baseline in the Result of SMAQ Questionnaire Adjusted for the Effect of Covariables

The SMAQ questionnaire evaluates medication adherence. It provides a dichotomic result of adherence (yes/no), and a semiquantitative estimate of adherence. Greater than 95% adherence is considered as adherent, and less than 95% as non-adherent.

Time frame: Baseline, 16 weeks.

Secondary Outcomes

ART adherence measured by SMAQ Questionnaire at 4, 8 and 12 weeks of intervention

SMAQ provides a dichotomic result of adherence (yes/no): we will report percentage of participants adherent to ART per study group during the intervention.

Time frame: 4, 8 and 12 weeks of intervention

Loss to follow-up

Loss to follow-up is defined as either (i) participants not responding to messages for ≥ 30 continuous days since receiving the intervention and not responding to messages or questionnaires at the end of their intervention period (t=16), or (ii) particip

Time frame: From the start of delivery intervention until study completion

Time of permanence in the study

Time of permanence in the study, indicated from the first date of intervention delivery until loss to-follow up or study completion. We will describe the median and interquartile range of this result in both study arms.

Time frame: Baseline until study completion (16 weeks).

Metrics on the use of a bidirectional platform for intervention delivery

Frequencies, percentages, and means with a standard deviation of messages and questionnaires programmed for sending, sent, received, read, and answered by participants. Frequencies and percentages of different process indicators self-reported by participants.

Time frame: End of the intervention at 16 weeks.